Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

Hepatology

Volumn 47, Issue 5, 2008, Pages 1453-1461

  Loustaud Ratti, Véronique ^a   Alain, Sophie ^b   Rousseau, Annick ^c   Hubert, Isabelle Fouchard ^d   Sauvage, François Ludovic ^c   Marquet, Pierre ^c   Denis, François ^b   Lunel, Françoise ^d   Calès, Paul ^d   Lefebvre, Annie ^a   Fauchais, Anne Laure ^a   Liozon, Eric ^a   Vidal, Elisabeth ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UMR 1092   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; N (4 AMINOBUTYL) 2 NAPSYLAMIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHRONIC HEPATITIS C; CLINICAL ARTICLE; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; NEUTROPENIA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIROLOGY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; GENOTYPE; HEPATITIS C; PHARMACODYNAMICS; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; PROTHROMBIN TIME; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 43949119161     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.22217     Document Type: Article

References (25)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
3. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19: 17-24.
4. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-565.
5. Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 349-361.
6. Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003; 47: 124-129.
7. Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-708.
8. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275-279.
9. Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. HEPATOLOGY 2003; 37: 1359-1367.
10. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al.; the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
11. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006; 63: 832-842.
12. Laskin OL, Longstreth JA, Hart CC, Scavuzzo D, Kalman CM, Connor JD, et al. Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Clin Pharmacol Ther 1987; 41: 546-555.
13. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62: 710-714.
14. Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol 2000; 49: 417-421.
15. Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47: 23-30.
16. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563-570.
17. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-714.
18. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972.
19. Dixit NM, Layden-Almer JE, Layden TJ, Prelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-924.
20. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003; 310: 333-342.
21. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43: 623-629.
22. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 2007; 81: 7732-7741.
23. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. HEPATOLOGY 2007; 46: 1548-1563.
24. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003; 77: 5933-5947.
25. Bruno R, Hille D, Riva A, Vivier N, Ten Bokkel Huinnink WW, Van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16: 187-196.